Published in Blood Weekly, November 10th, 2005
Cholestech is providing a high sensitivity C-Reactive Protein (hs-CRP) test for the Cholestech LDXSystem to rapidly prescreen patients for eligibility to participate in a global multisite clinical study, sponsored by AstraZeneca.
"We know that individuals with increased blood levels of hs-CRP are at high risk for heart attack and stroke, even if they have normal cholesterol levels," said Dr. Paul Ridker, a cardiologist at the Brigham and Women's Hospital in Boston, Massachusetts, and principal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.